EndoBreast Study - Assessment of Feasibility, Functional Outcomes, and Sensitivity of the Areola-Nipple Complex in Endoscopic Mastectomy

NCT07718425 | Recruiting

• 1 other identifier: CE163/2026
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Study Design Prospective, single-center, observational, non-interventional study conducted in routine clinical practice. No investigational treatments or modifications to standard diagnostic, therapeutic, or follow-up procedures are planned. Consecutive eligible patients undergoing endoscopic nipple-sparing mastectomy (NSM) with immediate breast reconstruction will be prospectively enrolled. Background and Rationale Nipple-sparing mastectomy with immediate reconstruction is an established treatment for selected patients with breast cancer and women undergoing prophylactic mastectomy because of hereditary risk. Preservation of the nipple-areola complex (NAC) improves cosmetic outcomes, body image, and patient satisfaction while maintaining oncological safety. Endoscopic NSM is a minimally invasive alternative that may reduce scarring, surgical trauma, and recovery time while improving aesthetic outcomes without compromising oncological radicality. However, evidence remains limited, particularly in Europe, regarding feasibility, perioperative safety, sensory recovery, quality of life, reconstructive outcomes, and long-term oncological results. This study aims to prospectively collect real-world data from a consecutive cohort treated at a specialized breast center. Primary Objective To evaluate the feasibility and surgical safety of endoscopic NSM with immediate breast reconstruction in patients undergoing prophylactic or therapeutic mastectomy. Secondary Objectives To evaluate NAC sensory recovery at 6 and 12 months; assess oncological safety through surgical radicality and follow-up; evaluate quality of life and patient satisfaction using validated questionnaires; describe disease-free survival (DFS), overall survival (OS), reconstructive and aesthetic outcomes; and assess postoperative hospital stay. Primary Endpoints Overall incidence of early surgical complications; incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss; recovery of NAC sensation at 6 and 12 months; and pathological assessment of retroareolar margin status. Secondary Endpoints BREAST-Q scores; local, regional, and distant recurrence; DFS; OS; and reconstructive/aesthetic outcomes. Study Population and Sample Size Thirty consecutive adult women undergoing prophylactic or therapeutic NSM with immediate implant-based reconstruction according to multidisciplinary evaluation. Main Inclusion Criteria Female; age 18-75 years; indication for prophylactic or therapeutic NSM; breast volume suitable for endoscopic surgery; Regnault ptosis ≤ Grade II; eligibility for immediate implant-based reconstruction; WHO/ECOG performance status \<3; written informed consent. Main Exclusion Criteria Inflammatory breast cancer or skin involvement; previous breast cancer surgery or radiotherapy to the affected breast; BMI \>35 kg/m²; active smoking; ASA Physical Status \>2; pregnancy or breastfeeding; inability to provide informed consent; participation in incompatible interventional clinical trials. Observed Procedure Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow. Data Collection and Follow-up Clinical, surgical, pathological, perioperative, and follow-up data will be prospectively recorded in a dedicated electronic Case Report Form. Patient-reported outcomes will be assessed using the validated BREAST-Q Reconstruction Module. Assessments will be performed preoperatively, intraoperatively, at 30 and 60 days, 6 months, 12 months, and annually up to 5 years. BREAST-Q will be administered at 6 months, 12 months, and annually thereafter. Study Duration Enrollment will continue until 30 patients have been recruited. Each participant will be followed for 5 years. Statistical Analysis This descriptive exploratory study will summarize categorical variables as frequencies and percentages and continuous variables using appropriate descriptive statistics. Long-term oncological outcomes will be reported as observed events, with DFS and OS estimated using Kaplan-Meier analysis when appropriate. Ethics The study is observational and does not alter routine clinical management. No additional significant risks beyond standard surgical care are anticipated. Written informed consent is mandatory. Personal data will be pseudonymized and processed in accordance with the General Data Protection Regulation (EU 2016/679) and applicable national legislation. Expected Benefits and Risks The study will provide prospective evidence on the feasibility, safety, functional recovery, quality of life, reconstructive outcomes, and oncological effectiveness of endoscopic NSM.

Conditions

Breast Cancer; Breast Reconstruction

Keywords

endoscopic mastectomy; breast cancer

Outcome Measures

Primary Outcomes (3)

• Overall incidence of early surgical complications

  incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss

  adverse events in the first 90 days

• recovery of NAC sensation

  NAC sensitivity is assessed at five anatomical points: the four quadrants of the areola and the nipple tip. Two complementary tests are used: * Cutaneous pressure threshold - Semmes-Weinstein Monofilaments (SWMs): a standardized set of 5 monofilaments with logarithmic force values of 2.83, 3.61, 4.31, 4.56, and 6.65 is applied perpendicularly to each point until the filament bends. The lightest filament perceived by the patient defines the sensory threshold at that point. * Spatial discrimination - Weber Two-Point Discrimination Test (TPD): two-point discrimination is evaluated at the four areolar quadrants using a calibrated aesthesiometer; the minimum distance at which the patient can distinguish two separate points is recorded (mm).

  6-12 months

• pathological assessment of retroareolar margin status

  For histological examination of the retroareolar tissue (intraoperative and/or final), the disc-shaped tissue fragment must be submitted with the surface facing the nipple (the "true margin") marked with a suture tag or a metal clip. Examination of the retroareolar parenchyma may be performed during surgery as an intraoperative frozen-section examination, or after surgery as a final examination. The retroareolar fragment, generally single, is measured (maximum diameter and thickness), and the surface facing the nipple must be marked by the pathologist with India ink. Both the frozen-section and the final histopathological examination are performed using serial sections approximately 5 mm apart, from the nipple-facing surface to the breast-facing surface, on the entire submitted specimen. For the intraoperative histological examination, an average of 3 frozen-tissue sections are prepared at 200-300 micron intervals, followed by an additi

  1 month

Secondary Outcomes (5)

• Reconstruction Module Pre- and Postoperative Scales BREAST-Q® Version 2.0

  5 years

• local, regional, and distant recurrence

  5 years

• Disease free survival (DFS)

  5 years

• Overall survival (OS)

  5 years

• reconstructive/aesthetic outcomes

  1 year

Study Arms (1)

Breast cancer patients

breast cancer patients recruited for endoscopic mastectomy

Procedure: endoscopic mastectomy

Interventions

endoscopic mastectomy PROCEDURE

Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow.

Breast cancer patients

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Thirty consecutive adult women undergoing prophylactic or therapeutic NSM with immediate implant-based reconstruction according to multidisciplinary evaluation.

You may qualify if:

• Female; age 18-75 years;
• indication for prophylactic or therapeutic NSM;
• breast volume suitable for endoscopic surgery;
• Regnault ptosis ≤ Grade II;
• eligibility for immediate implant-based reconstruction;
• WHO/ECOG performance status \<3;
• written informed consent.

You may not qualify if:

• Inflammatory breast cancer or skin involvement;
• previous breast cancer surgery or radiotherapy to the affected breast;
• BMI \>35 kg/m²; active smoking; ASA Physical Status \>2;
• pregnancy or breastfeeding;
• inability to provide informed consent;
• participation in incompatible interventional clinical trials.

Sponsors & Collaborators

• Massimiliano Bortolini: lead

Study Sites (1)

Ospedale degli Infermi ASL BI

Ponderano, BI, 13875, Italy

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Massimiliano Bortolini, MD

CONTACT

003901515156616; massimiliano.bortolini@aslbi.piemonte.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: MD, Breast Unit Head, Ospedale degli Infermi ASL BI

Study Record Dates

• First Submitted: July 6, 2026
• First Posted: July 22, 2026
• Study Start: June 23, 2026
• Primary Completion (Estimated): June 30, 2031
• Study Completion (Estimated): June 30, 2031
• Last Updated: July 22, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)